Cargando…
Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin
Cardiotoxicity represents the major side-effect limiting the clinical use of anthracyclines, especially doxorubicin, in cancer chemotherapy. The use of non-toxic prodrugs, or of liposome-encapsulated drugs, allows a better targeting of the tumours and may, therefore, improve the tolerance to the tre...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
1999
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374342/ https://www.ncbi.nlm.nih.gov/pubmed/10487608 http://dx.doi.org/10.1038/sj.bjc.6690646 |